Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 12, 2016 3:34 AM ET


Company Overview of Moderna Therapeutics, Inc.

Company Overview

Moderna Therapeutics, Inc. develops messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. It also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. The company focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology. Moderna Therapeutics, Inc. has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals, Inc.; and strategic collaborations with Karolinska Institutet, Institut Pasteur, and Karolinska University Hospital. The company was incorporated in 2009 and is based...

200 Tech Square

Cambridge, MA 02139

United States

Founded in 2009





Key Executives for Moderna Therapeutics, Inc.

Founding Chief Executive Officer, President and Director
Age: 42
Co-Founder, Chairman and Member of Technology Advisory Board
Age: 52
Chief Financial Officer
Age: 41
President of Research and Development
Age: 61
Senior Vice President of Technology Strategy
Age: 56
Compensation as of Fiscal Year 2015.

Moderna Therapeutics, Inc. Key Developments

Moderna Therapeutics, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-11-2016 10:45 AM

Moderna Therapeutics, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-11-2016 10:45 AM. Venue: The Waldorf Astoria, New York, New York, United States.

Moderna Therapeutics Licenses New Vaccine Candidates Against a New Viral Target to Merck

Moderna Therapeutics announced that Merck has licensed a vaccine program against an undisclosed viral target, including mRNA 1566 and a set of related novel vaccine candidates, as part of the ongoing collaboration between the companies to discover and develop vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). The inclusion of this new program, which was not part of the original collaboration agreement, follows the rapid progress made in the first year of the collaboration. Under the terms of the amendment, Moderna has licensed a vaccine program against an undisclosed viral target, including mRNA 1566 and a set of related novel vaccine candidates to Merck. mRNA 1566 has shown promising results in early development efforts undertaken by the Valera team. Moderna will receive an upfront payment for this program and will be eligible to receive development, regulatory and commercial milestone payments related to the new target, as well as tiered royalties on net sales of resulting products. Consistent with the existing collaboration, Merck will lead the development of the candidate and commercialization of any products resulting from the agreement, while Moderna will design and synthesize the mRNA vaccine candidates directed against selected targets. As part of the initial three-year research agreement announced in January 2015, Merck made an upfront cash payment of $50 million and a $50 million equity investment to utilize granted licenses to commercialize five product candidates.

AstraZeneca, MedImmune and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNATherapeutics

AstraZeneca, along with MedImmune, and announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology. The collaboration will combine MedImmune’s protein engineering and cancer biology expertise with Moderna’s mRNA platform. Under the terms of the new agreement, AstraZeneca and Moderna have agreed to collaborate on two specific immuno-oncology programs, based on promising pre-clinical data, including pharmacology in tumor models. Moderna will fund and be responsible for discovery and preclinical development of product candidates, with the aim of delivering one Investigational New Drug (IND) application-ready molecule for each of the two programs. Moderna’s efforts will be led by its oncology-focused venture, Onkaido. AstraZeneca will be responsible for early clinical development, led by MedImmune, and Moderna and AstraZeneca will share the costs of late-stage clinical development. The two companies will co-commercialize resulting products in the US under a 50:50 profit sharing arrangement. AstraZeneca will lead ex-US commercialization efforts, with Moderna receiving tiered royalties up to substantial double digits on ex-US sales. Under the companies original strategic agreement, AstraZeneca holds exclusive access to select any target of its choice in cardiometabolic diseases, as well as select targets in oncology, over a period of up to five years for subsequent development in mRNA. Several projects are progressing towards clinical development under the arrangement, and a first-in-human study is expected to commence in late 2016. With its novel technology to enable mRNA as a drug, Moderna is building a fully scaled drug discovery and development platform centered on the rapid and low-cost design, delivery and production of mRNA drug candidates. Moderna is also advancing an innovative business model built on the decentralization of drug development activities. With an ecosystem of in-house concept development, ventures focused on therapeutic areas and a cluster of major pharma and biotech partners, Moderna is enabling more than 90 discovery and preclinical programs across oncology, infectious diseases, rare diseases and cardiovascular diseases. Moderna’s pipeline also covers a broad expanse of novel drug modalities, each representing a distinct approach to using the company’s novel mRNA expression platform to encode proteins that achieve a therapeutic benefit.

Similar Private Companies By Industry

Company Name Region
Edge BioServ, LLC United States
Immune Cell Therapy, Inc. United States
Nortis Inc. United States
Amunix Operating Inc. United States
MIGENIX Corp. United States

Recent Private Companies Transactions

Private Placement
October 22, 2015
Valera LLC

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Moderna Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at